Coya Therapeutics (NASDAQ:COYA) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report report published on Monday morning,Benzinga reports. HC Wainwright currently has a $18.00 target price on the stock.

A number of other brokerages have also recently issued reports on COYA. BTIG Research upped their price target on shares of Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Lake Street Capital reaffirmed a “buy” rating and issued a $17.00 target price on shares of Coya Therapeutics in a report on Wednesday, November 5th. Chardan Capital reiterated a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Thursday, January 8th. D. Boral Capital reissued a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a research report on Wednesday, January 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Coya Therapeutics Stock Up 1.9%

Coya Therapeutics stock opened at $4.74 on Monday. Coya Therapeutics has a twelve month low of $3.94 and a twelve month high of $8.29. The company has a market capitalization of $99.16 million, a P/E ratio of -4.27 and a beta of 0.27. The stock’s 50 day moving average is $5.38 and its 200 day moving average is $5.88.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.12). Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.The company had revenue of $3.56 million during the quarter, compared to the consensus estimate of $3.70 million. As a group, equities analysts expect that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Investors Weigh In On Coya Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC grew its holdings in shares of Coya Therapeutics by 51.3% in the third quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock worth $372,000 after acquiring an additional 22,120 shares during the period. Dauntless Investment Group LLC lifted its holdings in Coya Therapeutics by 199.5% in the third quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after acquiring an additional 101,932 shares during the period. CM Management LLC boosted its position in Coya Therapeutics by 16.7% in the fourth quarter. CM Management LLC now owns 350,000 shares of the company’s stock worth $2,030,000 after purchasing an additional 50,000 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new position in Coya Therapeutics in the fourth quarter worth about $81,000. Finally, Prosperity Wealth Management Inc. grew its stake in shares of Coya Therapeutics by 16.4% during the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after purchasing an additional 3,350 shares during the period. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.